List view / Grid view
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
Researchers in the US have found that antibodies to the SARS-CoV-2 Spike protein can be produced in hen eggs.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Eli Lilly scientists report that they have designed, qualified and enabled a high-throughput plasmid purification and quantification workstation.
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
Read about the latest addition Invitrogen™ TrueCut™ HiFi Cas9 Protein to support your application and research goals.
Researchers at Children’s National Hospital in the US have developed a promising new gene therapy for limb-girdle muscular dystrophy (LGMD) 2B.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
